Theravance Biopharma (TBPH) announced on Thursday that Viatris has received regulatory approval in China for Yupelri, a once-daily nebulized treatment for chronic obstructive pulmonary disease.
The company stated that the approval would result in a $7.5 million milestone payment to Theravance from Viatris, expected in Q3, and that it could also earn up to $37.5 million in future sales-based milestones, as well as 14-20% royalties on Chinese net sales.
Viatris is responsible for all aspects of the development and commercialization of Yupelri in China, it added.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。